Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 8/20 | 0.35 |
| ▸ | HTR1D | P28221 | 8/20 | 0.35 |
| ▸ | HTR1B | P28222 | 8/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18478102 | 0.84 | HRH4 (0.41) | HRH4KITTLR9TLR7HTR1A | |
| SCHEMBL20409205 | 0.83 | IDE (0.36) | HRH4KITTLR9TLR7HTR1A | |
| SCHEMBL18437140 | 0.82 | HRH4 (0.39) | HRH4KITTLR9TLR7HTR1A | |
| SCHEMBL20463563 | 0.80 | CYP11B2 (0.38) | KITTLR9TLR7GABRG2GABRB3 | |
| SCHEMBL20435587 | 0.76 | GABRG2 (0.36) | GABRG2GABRB3GABRA5 | |
| SCHEMBL18485086 | 0.76 | KDM4E (0.39) | KITGABRG2GABRB3GABRA5 | |
| SCHEMBL18437191 | 0.76 | HRH4 (0.43) | HRH4KITTLR9TLR7HTR1A | |
| SCHEMBL20436874 | 0.73 | CHRM2 (0.39) | GABRG2GABRB3GABRA5 | |
| SCHEMBL20435585 | 0.73 | MAP2K4 (0.37) | GABRG2GABRB3GABRA5ACHE | |
| SCHEMBL18437165 | 0.72 | TSHR (0.39) | KITGABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221341-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180214429-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214429-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | HRH4 2732/4885KIT 778/4885TLR9 4496/4885 |
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | HRH4 3066/4885KIT 641/4885TLR9 4488/4885 |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | HRH4 3617/4885KIT 823/4885TLR9 4713/4885 |
| US-20180221341-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | HRH4 3195/4885KIT 651/4885TLR9 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.